Literature DB >> 27601362

Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.

Nikolaos Miaris1, Maria Maltezou2, George Papaxoinis3, Anastasios Visvikis4, Epaminontas Samantas4.   

Abstract

Entities:  

Keywords:  Anti-VEGF agents; Proteinuria; Renal carcinoma; Reversible posterior leukoencephalopathy syndrome; Tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2016        PMID： 27601362     DOI： 10.1016/j.clgc.2016.08.005

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  8 in total

Review 1.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

Review 2.  Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.

Authors:  Shoichi Deguchi; Koichi Mitsuya; Yoko Nakasu; Nakamasa Hayashi; Hirohisa Katagiri; Hideki Murata; Junji Wasa; Mitsuru Takahashi; Masahiro Endo
Journal:  Invest New Drugs       Date:  2017-10-25       Impact factor: 3.850

3.  Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature.

Authors:  Yajuan Lv; Yan Zhang; Jiandong Zhang; Ning Liang; Fengjun Liu; Ruixue Liu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Nephrotic Syndrome and Atypical Posterior Reversible Encephalopathy Syndrome in a Patient with Parkinson's Disease.

Authors:  Ryo Tokimura; Eiichi Ito; Yoshihiro Sugiura; Yoshikazu Ugawa
Journal:  Intern Med       Date:  2021-12-18       Impact factor: 1.282

5.  Pazopanib-induced Endothelial Injury with Podocyte Changes.

Authors:  Keisuke Maruyama; Naoki Nakagawa; Ayana Suzuki; Maki Kabara; Motoki Matsuki; Motohiro Shindo; Yayoi Ogawa; Naoyuki Hasebe
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

Review 6.  Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Authors:  Young Kwang Chae; Lauren Chiec; Scott K Adney; Josh Waitzman; Ricardo Costa; Benedito Carneiro; Maria Matsangou; Mark Agulnik; Peter Kopp; Frank Giles
Journal:  Oncotarget       Date:  2018-06-15

7.  Pazopanib-induced posterior reversible encephalopathy syndrome with possible syndrome of inappropriate secretion of antidiuretic hormone: an incidental or pathophysiological association?

Authors:  Jonathan Wong So; Bérenger Largeau; Frédérique Beau-Salinas; Stephan Ehrmann; Christophe Magni; Jérôme Meunier
Journal:  Neural Regen Res       Date:  2020-06       Impact factor: 5.135

8.  Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review.

Authors:  Ying Chen; Xiaoming Ling; Wencui Kong; Shuiliang Wang; Zongyang Yu
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.